Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C26644
http://purl.obolibrary.org/obo/NCIT_C26644
|
|---|---|
| Preferred Name | Eribulin Mesylate |
| Definitions |
The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The mesylate salt of a synthetic analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression. |
|---|---|
| label | Eribulin Mesylate
|
| prefLabel | Eribulin Mesylate
|
| Has_Free_Acid_Or_Base_Form | |
| Legacy Concept Name | E7389
|
| in_subset |
See more
See less
|
| Preferred_Name | Eribulin Mesylate
|
| Is_Value_For_GDC_Property | |
| Chemical_Formula | C40H59NO11.CH4O3S
|
| Display_Name | Eribulin Mesylate
|
| Maps_To | Eribulin Mesylate
|
| PDQ_Open_Trial_Search_ID | 257773
|
| Has_Target | |
| UMLS_CUI | C2608038
|
| FDA_UNII_Code | AV9U0660CW
|
| prefixIRI | NCIT:C26644
|
| Accepted_Therapeutic_Use_For | unresectable or metastatic liposarcoma; breast cancer
|
| NCI_Drug_Dictionary_ID | 257773
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C26644
|
| type | |
| ALT_DEFINITION | A drug used to treat metastatic breast cancer in patients who have already been treated with other chemotherapy. It is also being studied in the treatment of other types of cancer. Halaven may block cancer cell growth by stopping cell division. It belongs to the family of drugs called antitubulin agents.
|
| NSC Number | 707389
|
| PDQ_Closed_Trial_Search_ID | 257773
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| CAS_Registry | 253128-41-5
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |